MicrobeWorld App

appsquarebannerad200x200

Join MicrobeWorld

Subscribe via Email

subscribe

Microbes After Hours

cheese-thumb-small

Click for more "Microbes After Hours" videos

Featured Image

Featured Video

Crowdsourced Microbes Heading to Station

Supporters

ASM House 200X200

Vical gets US patent cover for herpes simplex DNA vaccine

Vical Incorporated announced the issuance of US Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type-2 (HSV-2). HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Vical is collaborating under a previously disclosed grant on the preclinical development of an HSV-2 vaccine which will be designed for use in people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral shedding and transmission. The vaccine will be evaluated with Vical's Vaxfectin adjuvant.

The new '993 patent covers DNA vaccines targeting a specific HSV-2 protein, formulated with or without Vical's Vaxfectin adjuvant. It adds to Vical's family of patents in the United States and other key regions based on the company's discovery that administering genetic sequences such as DNA or RNA into the body, without the use of viral delivery vehicles, may cause expression of the proteins encoded by the genetic sequences. Vical has additional issued patents covering the composition and use of the Vaxfectin adjuvant.
 
 

Comments (0)

Collections (0)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use